Pliant Therapeutics Inc (PLRX) — Titan Protect Analysis

PLRX

Pliant Therapeutics Inc

Healthcare · ·

$1.15

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$71M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.11

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-53.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.00

+161% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 3 analysts covering this stock

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based t

https://pliantrx.com

Country: United States Employees: 49 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.656

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1173

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.743

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-69.1%

Historical annualised return based on price data

Max Drawdown

-93.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

295

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$1.95

41% below the year high

52W Low

$1.09

6% above the year low

Avg Volume

509,979

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.83

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

17.43

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-61,810,124

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-113,218,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$3.00

Target Median

$3.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go